Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 3/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402320 | 1.00 | DPP4 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL31174307 | 1.00 | DPP4 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30353290 | 0.94 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7218621 | 0.90 | MME (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL5579160 | 0.90 | MME (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL5579158 | 0.90 | MME (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7218624 | 0.90 | MME (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL31174304 | 0.90 | MME (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27663801 | 0.90 | MME (0.43) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL10803670 | 0.90 | MME (0.43) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| EP-4743479-A1 | ADENOVIRUSES | Theolytics Ltd. (GB) | 2026-05-20 | — | — | EP | claimed |
| EP-4743101-A1 | MUTATED ADENOVIRUSES WITH IMPROVED REPLICATION AND THEIR USE FOR TREATING CANCER | Theolytics Ltd. (GB) | 2026-05-20 | — | — | EP | claimed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| WO-2025149667-A1 | ANTIBODY DRUG CONJUGATES AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2025-07-17 | — | — | WO | claimed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | claimed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| EP-4554623-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | claimed |
| US-20230151065-A1 | MULTI-DISULFIDE-BOND LONG-CHAIN PEPTIDE WITH NEUROPROTECTIVE ACTIVITY, PHARMACEUTICAL COMPOSITION AND APPLICATION | NANTONG UNIVERSITY (CN) | 2023-05-18 | — | — | US | claimed |
| EP-3838893-B1 | LINKER, ANTIBODY-DRUG CONJUGATE INCLUDING SAME, AND USE THEREOF | ACAD OF MILITARY MEDICAL SCIENCES (CN) | 2023-04-19 | — | — | EP | claimed |
| CN-112543752-B | Linker, antibody conjugate drug containing linker and use of linker | 中国人民解放军军事科学院军事医学研究院 | 2023-04-18 | — | — | CN | claimed |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2023-03-30 | — | — | US | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| WO-2022196858-A1 | AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS, COMPRISING SAME | (주)프레이저테라퓨틱스 | 2022-09-22 | — | — | WO | claimed |
| CN-114774395-A | High-purity chitinase 3-like protein 1 epitope peptide for liver disease detection and preparation method thereof | 亿彤科技发展(福建)有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| CN-106455664-A | Composition with high content of cyclic dipeptide | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | DPP4 3876/4885DPP8 2230/4885DPP9 1972/4885 |
| US-20230094471-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | GABBR2, GABRB1, GABRB2 | DPP4 4586/4885DPP8 4829/4885DPP9 4796/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | DPP4 860/4885DPP8 2001/4885DPP9 1994/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | DPP4 4452/4885DPP8 4691/4885DPP9 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.